PitchSend

Investor Presentaiton

Icodec - key take aways R&D investor presentation 14 Once-weekly insulin icodec showed in the phase 2 trial numerically lower HbA1c reduction compared to glargine U100 significantly better post-prandial glucose control half of patients reached the HbA 1c target of ≤6.5% Icodec appeared to have a safe profile Icodec phase 3 programme expected to begin in Q4 2020 Aim to demonstrate superiority on HbA1c and time in range

View entire presentation